Table 2

Description of normal control subjects

Normal subject no.SexAgeDermatology Clinic treatmentaL-Ferritin (μg/L)bH-Ferritin (μg/L)bRatio H-Ferritin: L-Ferritin% of CD4+CD25+CD69 regulatory T cells
1F2376.788.11.17.9%
2F2318.428.31.5n.a.c
3M2750.942.40.83.7%
4M29117.0105.90.910.1%
5M39127.7104.60.84.2%
6M39Psoriasis96.1133.71.410.7%
7F4092.2109.81.27.9%
8F4750.820.90.4n.a.
9M50126.6138.31.18.2%
10M53Psoriasis178.6146.60.810.2%
11M55104.9129.51.211.0%
12F60110.670.80.614.4%
13F62Pruritis54.844.30.8n.a.
14M62250.7157.50.63.8%
15F65Basal cell carcinoma47.350.51.115.5%
16M68Dermatitis88.9120.21.4n.a.
17F70Basal cell carcinoma86.687.31.014.9%
18M75Solar keratosis138.2109.00.84.8%
19M81Squamous carcinoma139.9119.70.9n.a.
  • a Attending the Royal Newcastle Dermatology Clinic.

  • b Detection using ferritin ELISA.

  • c n.a., not available.